No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
LLY250117P1060000
- 272.24
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
0.00Open272.24Pre Close0 Volume0 Open Interest1060.00Strike Price0.00Turnover0.00%IV2.53%PremiumJan 17, 2025Expiry Date251.83Intrinsic Value100Multiplier-9DDays to Expiry20.41Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.97Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Obesity Drug Developer Metsera Sets Terms for $275M IPO
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Akero Therapeutics Stock Doubles on Liver Data -- Barrons.com
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $997
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,146